SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced the approval of new inducement awards by the Compensation Committee of its Board of Directors on June 6, 2025. Under Acadia's 2024 Inducement Plan, 41 new employees have been granted non-qualified stock options to purchase 187,664 shares of common stock and 89,582 restricted stock units (RSUs). The stock options have an exercise price of $21.98 per share, aligned with the closing trading price on the grant date, and are set to vest over four years. The RSUs will also vest over a four-year period, with 50% vesting on the second anniversary of the grant date. These awards are contingent upon the employees' continued service with Acadia and are governed by the terms of the 2024 Inducement Plan and corresponding award agreements.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。